Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Oral Zinc Therapy for the Prevention of Mucositis

This study has been completed.
Information provided by:
Sheba Medical Center Identifier:
First received: March 18, 2007
Last updated: October 2, 2008
Last verified: October 2008
Zinc is an intracellular mineral with important enzymatic cofactor activities for cell membrane stability, DNA and RNA structure. Zinc deficiency is associated with delayed wound healing and immune dysfunction. In patietns with hematological malignancies an inverse correlation was found between disease stage and zinc level. Patients undergoing high dose chemotherapy for hematologic malignancies are predisposed to develop oral and gastrointestinal complications, in particular oral mucositis. These patients may have relative zinc deficiency, therefore oral zinc therapy may be benefical in the prevention of these complications.

Condition Intervention Phase
Drug: Zinc
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • Maximal Mucositis grade [ Time Frame: day -7 to day +21 or discharge day ]

Secondary Outcome Measures:
  • Duration of maximal mucositis grade [ Time Frame: day -7 to day +21 or discharge day ]
  • Overall duration of mucositis [ Time Frame: day -7 to day +21 or discharge day ]
  • Duration of severe neutropenia [ Time Frame: day -7 to day +21 or discharge day ]
  • Duration of febrile neutropenia [ Time Frame: day -7 to day +21 or discharge day ]

Estimated Enrollment: 40
Study Start Date: April 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Oral zinc therapy, intervention
Drug: Zinc
Oral Zincol 1 Tab TID from day -6/-7 until discharge
Placebo Comparator: 2
oral placebo
Drug: Placebo
Oral placebo 1 Tab TID from day -6/-7 until discharge

Detailed Description:

Patients candidate for High dose chemotherapy with stem cell support for the diagnosis of relapsed/resistant Hodgkins or NHL or MM will be screened for enrollment in the study.

Patients will be randomized in a 1:1 ratio to therapy with either zincol 1 Tab TID or placebo 1 Tab TID.

Therapy will start on the morning before commencing chemotherapy and will continue untill the first of either discharge day or day 21.

Response assesment will include:

  1. Mucositis assesment using NCI-CTC and OMAS scores- to be done eod from baseline and untill day 21/discharge day if before day 21
  2. Evaluation of zinc levels in the serum, PBMC and saliva- to be done at baseline, day 6/7 and day 21/discharge day if before day 21.
  3. Collection of clinical outcome data regarding infectious complications including- presence and length of febrile neutropenia,use of antibacterial and antifungal medications,

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients undergoing high dose chemotherapy with stem cell support for relapsed or resistant Hodgkins or NHL (treated with BEAM protocol) or MM (treated with high dose melphalan).
  • ECOG performance less than or equal to 2
  • Adequate renal and hepatic function

Exclusion Criteria:

  • Presence of any other active malignancy other than BCC of the skin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00449592

Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center
Ramat-Gan, Israel
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Maya Koren-Michowitz, MD Sheba Medical Center
  More Information

Responsible Party: Dr. Maya Koren-Michovitz, Sheba Medical Center Identifier: NCT00449592     History of Changes
Other Study ID Numbers: SHEBA-06-4196-MKM-CTIL
Study First Received: March 18, 2007
Last Updated: October 2, 2008

Keywords provided by Sheba Medical Center:
Stem cell transplantation

Additional relevant MeSH terms:
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases
Trace Elements
Growth Substances
Physiological Effects of Drugs processed this record on April 28, 2017